United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $502.35, for a total value of $4,772,325.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $162,983,941.05. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $497.11 on Friday. The firm has a market cap of $21.32 billion, a price-to-earnings ratio of 17.79, a price-to-earnings-growth ratio of 2.51 and a beta of 0.56. The business has a 50-day simple moving average of $520.91 and a two-hundred day simple moving average of $540.30. United Therapeutics Corporation has a fifty-two week low of $396.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the firm posted $6.41 EPS. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on UTHR. Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. increased their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Finally, Royal Bank Of Canada reduced their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arjuna Capital boosted its stake in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares during the last quarter. Sage Rhino Capital LLC increased its stake in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC raised its holdings in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares during the period. Meeder Advisory Services Inc. raised its holdings in United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares during the period. Finally, Independent Advisor Alliance lifted its position in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.